These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions. Virtanen E, Kalliala I, Dyba T, Nieminen P, Auvinen E. Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961 [Abstract] [Full Text] [Related]
5. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J. Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437 [Abstract] [Full Text] [Related]
7. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930 [Abstract] [Full Text] [Related]
9. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data. Fu Y, Li X, Li Y, Lu W, Xie X, Wang X. Microbiol Spectr; 2022 Feb 23; 10(1):e0157021. PubMed ID: 35171029 [Abstract] [Full Text] [Related]
10. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M. BMC Cancer; 2015 Dec 16; 15():968. PubMed ID: 26674353 [Abstract] [Full Text] [Related]
11. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan. Kuroki H, Sakamoto J, Shibata T, Takakura M, Sasagawa T. J Med Virol; 2021 Aug 16; 93(8):5076-5083. PubMed ID: 33634473 [Abstract] [Full Text] [Related]
13. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan. Nakamura M, Nakade K, Orisaka S, Iwadare J, Mizumoto Y, Fujiwara H. Am J Clin Pathol; 2019 Feb 04; 151(3):263-269. PubMed ID: 30260388 [Abstract] [Full Text] [Related]
16. Immediate histologic correlation in women with atypical squamous cells of undetermined significance cytology and positive high-risk HPV: A retrospective review of 6000 cases in a large academic women's hospital. Zhang H, Pradhan D, Wang T, Ashman D, Matsko J, Zhao C. Cancer Cytopathol; 2020 Nov 04; 128(11):852-859. PubMed ID: 32639689 [Abstract] [Full Text] [Related]
18. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. Basu P, Banerjee D, Mittal S, Dutta S, Ghosh I, Chowdhury N, Abraham P, Chandna P, Ratnam S. J Med Virol; 2016 Jul 04; 88(7):1271-8. PubMed ID: 26693677 [Abstract] [Full Text] [Related]